Anaphylaxis and mortality induced by treatment of mice with anti-VLA-4 antibody and pertussis toxin

Journal of Immunology

Volumn 186, Issue 5, 2011, Pages 2750-2756

  Ji, Niannian ^a   Rao, Nagarjun ^b   Guentzel, Neal M ^a   Arulanandam, Bernard P ^a   Forsthuber, Thomas G ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; PERTUSSIS TOXIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN MONOCLONAL ANTIBODY;

ALLERGIC ENCEPHALOMYELITIS; ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVATION; IMMUNE RESPONSE; INNATE IMMUNITY; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TOXICITY TESTING;

ANAPHYLAXIS; ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; DRUG COMBINATIONS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INTEGRIN ALPHA4BETA1; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; MYELIN-ASSOCIATED GLYCOPROTEIN; PERTUSSIS TOXIN; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952750287     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000907     Document Type: Article

References (48)

1. Compston, A., and A. Coles. 2002. Multiple sclerosis. [Published erratum appears in 2002 Lancet 360: 648.] Lancet 359: 1221-1231.
2. Noseworthy, J. H., C. Lucchinetti, M. Rodriguez, and B. G. Weinshenker. 2000. Multiple sclerosis. N. Engl. J. Med. 343: 938-952.
3. Mokhtarian, F., D. E. McFarlin, and C. S. Raine. 1984. Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature 309: 356-358.
4. Steinman, L. 1996. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85: 299-302. (Pubitemid 26160700)
5. Gijbels, K., S. Engelborghs, and P. P. De Deyn. 2000. Experimental autoimmune encephalomyelitis: An animal model for multiple sclerosis. Neurosci. Res. Commun. 26: 193-206.
6. Wiśniewski, H. M., and A. B. Keith. 1977. Chronic relapsing experimental allergic encephalomyelitis: an experimental model of multiple sclerosis. Ann. Neurol. 1: 144-148.
7. Stone, S. H., and E. M. Lerner, II. 1965. Chronic disseminated allergic encephalomyelitis in guinea pigs. Ann. N. Y. Acad. Sci. 122: 227-241.
8. Goodin, D. S., B. A. Cohen, P. O'Connor, L. Kappos, and J. C. Stevens. 2008. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 71: 766-773.
9. Schreiner, B., B. C. Kieseier, H. P. Hartung, R. Hohlfeld, and H. Wiendl. 2005. Blocking adhesion molecules with natalizumab in multiple sclerosis. Nervenarzt 76: 999-1005. (Pubitemid 41187629)
10. Springer, T. A. 1990. Adhesion receptors of the immune system. Nature 346: 425-434.
11. Elices, M. J., L. Osborn, Y. Takada, C. Crouse, S. Luhowskyj, M. E. Hemler, and R. R. Lobb. 1990. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60: 577-584.
12. Shimizu, Y., W. Newman, Y. Tanaka, and S. Shaw. 1992. Lymphocyte interactions with endothelial cells. Immunol. Today 13: 106-112.
13. Baron, J. L., J. A. Madri, N. H. Ruddle, G. Hashim, and C. A. Janeway, Jr. 1993. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177: 57-68.
14. Steinman, L. 2005. Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab. Nat. Rev. Drug Discov. 4: 510-518.
15. Yednock, T. A., C. Cannon, L. C. Fritz, F. Sanchez-Madrid, L. Steinman, and N. Karin. 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356: 63-66.
16. Kent, S. J., S. J. Karlik, C. Cannon, D. K. Hines, T. A. Yednock, L. C. Fritz, and H. C. Horner. 1995. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. 58: 1-10.
17. Theien, B. E., C. L. Vanderlugt, T. N. Eagar, C. Nickerson-Nutter, R. Nazareno, V. K. Kuchroo, and S. D. Miller. 2001. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 107: 995-1006.
18. Niino, M., C. Bodner, M. L. Simard, S. Alatab, D. Gano, H. J. Kim, M. Trigueiro, D. Racicot, C. Guérette, J. P. Antel, et al. 2006. Natalizumab effects on immune cell responses in multiple sclerosis. Ann. Neurol. 59: 748-754.
19. Stüve, O., C. M. Marra, K. R. Jerome, L. Cook, P. D. Cravens, S. Cepok, E. M. Frohman, J. T. Phillips, G. Arendt, B. Hemmer, et al. 2006. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 59: 743-747.
20. Hofstetter, H. H., C. L. Shive, and T. G. Forsthuber. 2002. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J. Immunol. 169: 117-125.
21. Schneider, Y. J. 1989. Optimisation of hybridoma cell growth and monoclonal antibody secretion in a chemically defined, serum- and protein-free culture medium. J. Immunol. Methods 116: 65-77.
22. Merritt, E. A., and W. G. J. Hol. 1995. AB5 toxins. Curr. Opin. Struct. Biol. 5: 165-171.
23. Kaslow, H. R., and D. L. Burns. 1992. Pertussis toxin and target eukaryotic cells: binding, entry, and activation. FASEB J. 6: 2684-2690.
24. Su, S. B., P. B. Silver, M. F. Zhang, C. C. Chan, and R. R. Caspi. 2001. Pertussis toxin inhibits induction of tissue-specific autoimmune disease by disrupting G protein-coupled signals. J. Immunol. 167: 250-256.
25. Racke, M. K., W. Hu, and A. E. Lovett-Racke. 2005. PTX cruiser: driving autoimmunity via TLR4. Trends Immunol. 26: 289-291.
26. Vonderheide, R. H., and T. A. Springer. 1992. Lymphocyte adhesion through very late antigen 4: evidence for a novel binding site in the alternatively spliced domain of vascular cell adhesion molecule 1 and an additional alpha 4 integrin counter-receptor on stimulated endothelium. J. Exp. Med. 175: 1433-1442.
27. Reimann, T., D. Büscher, R. A. Hipskind, S. Krautwald, M. L. Lohmann-Matthes, and M. Baccarini. 1994. Lipopolysaccharide induces activation of the Raf-1/MAP kinase pathway. A putative role for Raf-1 in the induction of the IL-1 beta and the TNF-alpha genes. J. Immunol. 153: 5740-5749.
28. Remick, D. G., R. M. Strieter, M. K. Eskandari, D. T. Nguyen, M. A. Genord, C. L. Raiford, and S. L. Kunkel. 1990. Role of tumor necrosis factor-alpha in lipopolysaccharide-induced pathologic alterations. Am. J. Pathol. 136: 49-60.
29. Shapira, L., W. A. Soskolne, Y. Houri, V. Barak, A. Halabi, and A. Stabholz. 1996. Protection against endotoxic shock and lipopolysaccharide- induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect. Immun. 64: 825-828.
30. Tosato, G., and K. D. Jones. 1990. Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. Blood 75: 1305-1310.
31. Linthicum, D. S., J. J. Munoz, and A. Blaskett. 1982. Acute experimental autoimmune encephalomyelitis in mice. I. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitization and increased vascular permeability of the central nervous system. Cell. Immunol. 73: 299-310.
32. Yong, T., G. A. Meininger, and D. S. Linthicum. 1993. Enhancement of histamine-induced vascular leakage by pertussis toxin in SJL/J mice but not BALB/c mice. J. Neuroimmunol. 45: 47-52.
33. de Jong, E. C., P. L. Vieira, P. Kalinski, J. H. N. Schuitemaker, Y. Tanaka, E. A. Wierenga, M. Yazdanbakhsh, and M. L. Kapsenberg. 2002. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J. Immunol. 168: 1704-1709.
34. Hou, W. Q., Y. D. Wu, S. H. Sun, M. Shi, Y. Sun, C. H. Yang, G. Pei, Y. D. Gu, C. P. Zhong, and B. Sun. 2003. Pertussis toxin enhances Th1 responses by stimulation of dendritic cells. J. Immunol. 170: 1728-1736. (Pubitemid 36197387)
35. Ryan, M., L. McCarthy, R. Rappuoli, B. P. Mahon, and K. H. G. Mills. 1998. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28. Int. Immunol. 10: 651-662. (Pubitemid 28221466)
36. Shive, C. L., H. Hofstetter, L. Arredondo, C. Shaw, and T. G. Forsthuber. 2000. The enhanced antigen-specific production of cytokines induced by pertussis toxin is due to clonal expansion of T cells and not to altered effector functions of long-term memory cells. Eur. J. Immunol. 30: 2422-2431.
37. Wakatsuki, A., P. Borrow, K. Rigley, and P. C. L. Beverley. 2003. Cell-surface bound pertussis toxin induces polyclonal T cell responses with high levels of interferon-gamma in the absence of interleukin-12. Eur. J. Immunol. 33: 1859-1868.
38. Chen, X., O. M. Z. Howard, and J. J. Oppenheim. 2007. Pertussis toxin by inducing IL-6 promotes the generation of IL-17-producing CD4 cells. J. Immunol. 178: 6123-6129.
39. Schneider, O. D., A. A. Weiss, and W. E. Miller. 2007. Pertussis toxin utilizes proximal components of the T-cell receptor complex to initiate signal transduction events in T cells. Infect. Immun. 75: 4040-4049.
40. Denkinger, C. M., M. D. Denkinger, and T. G. Forsthuber. 2007. Pertussis toxin-induced cytokine differentiation and clonal expansion of T cells is mediated predominantly via costimulation. Cell. Immunol. 246: 46-54.
41. Luttrell, L. M., B. E. Hawes, T. van Biesen, D. K. Luttrell, T. J. Lansing, and R. J. Lefkowitz. 1996. Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gbetagamma subunit-mediated activation of mitogen-activated protein kinases. J. Biol. Chem. 271: 19443-19450.
42. Piiper, A., R. Gebhardt, B. Kronenberger, C. D. Giannini, R. Elez, and S. Zeuzem. 2000. Pertussis toxin inhibits cholecystokinin- and epidermal growth factor-induced mitogen-activated protein kinase activation by disinhibition of the cAMP signaling pathway and inhibition of c-Raf-1. Mol. Pharmacol. 58: 608-613.
43. Steinman, L. 2009. A molecular trio in relapse and remission in multiple sclerosis. Nat. Rev. Immunol. 9: 440-447.
44. Kivisakk, P., B. Healy, F. Quintana, H. Weiner, and S. Khoury. 2008. Increased expression of proinflammatory cytokines by peripheral blood leukocytes during natalizumab treatment in patients with multiple sclerosis. J. Neuroimmunol. 203: 268.
45. Kivisäkk, P., B. C. Healy, V. Viglietta, F. J. Quintana, M. A. Hootstein, H. L. Weiner, and S. J. Khoury. 2009. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 72: 1922-1930.
46. Krakauer, T., M. J. Buckley, and D. Fisher. 2010. Proinflammatory mediators of toxic shock and their correlation to lethality. Mediators of Inflammation 2010: 517594.
47. Diao, H., and M. Kohanawa. 2005. Endogenous interleukin-6 plays a crucial protective role in streptococcal toxic shock syndrome via suppression of tumor necrosis factor alpha production. Infect. Immun. 73: 3745-3748.
48. Stüve, O. 2008. The effects of natalizumab on the innate and adaptive immune system in the central nervous system. J. Neurol. Sci. 274: 39-41.